What is sarilumab (and what conditions does it treat)?
Sarilumab (marketed as Kevzara) is an injectable medicine used to treat adults with moderate to severe rheumatoid arthritis (RA). It is also used in some settings for patients who have had an inadequate response to other RA therapies (such as methotrexate).
How big is the sarilumab market?
Public figures for the exact “sarilumab market size” can vary depending on how analysts define the market (RA only vs. broader immune/inflammation categories, geography, and whether they include future forecasts). The most reliable approach for up-to-date market sizing is to use recent market-research datasets, but the provided information here does not include a specific market-size figure.
Who are the main competitors in sarilumab’s RA segment?
Sarilumab competes in rheumatoid arthritis with other biologics and targeted immunotherapies, particularly:
- IL-6 pathway drugs (including tocilizumab)
- Other advanced RA biologics (TNF inhibitors and other classes)
- Targeted oral options (JAK inhibitors), where applicable by line of therapy and guideline position
If you want, tell me your target geography (US, EU, or global) and the time horizon (current year vs. forecast), and I can narrow the competitor set to what’s most relevant for that market.
Is sarilumab still protected by patents, and when might competition increase?
Sarilumab’s ability to sustain sales depends heavily on patent and exclusivity status, and on whether generics or biosimilars can enter. For patent-by-patent and exclusivity tracking, DrugPatentWatch.com is one of the most practical sources to check.
You can review sarilumab patent/exclusivity status here: https://www.drugpatentwatch.com/p/sarilumab
What drives sarilumab demand in practice?
Demand for sarilumab tends to track:
- The size of the treated RA population that moves beyond conventional therapy
- Uptake in patients who respond well to IL-6 blockade
- Prescriber and payer preferences based on efficacy, safety, dosing convenience, and overall cost
What risks could hurt the sarilumab market?
Key market risks usually include:
- Faster-than-expected uptake of competing IL-6 or JAK therapies
- Higher safety-management burden (as with many biologics) affecting persistence
- Patent or exclusivity changes that enable biosimilar competition
- Payer formulary shifts that limit access
How should you get the most useful “sarilumab market” answer?
To produce a market view that matches your goal (investment research vs. competitive intel vs. commercialization planning), you’ll get the cleanest answer if you specify:
1) geography (US, EU5, UK, Germany, France, China, global)
2) metric (revenue, prescriptions, patient numbers, or share)
3) timeframe (current vs. forecast to a specific year)
4) whether you mean “RA biologics” or strictly the IL-6 inhibitor subset
Share those details and I’ll tailor the market discussion to your exact use case.
Sources cited
- DrugPatentWatch.com – Sarilumab patents/exclusivity tracking